Shares of GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) rose 0.4% on Monday . The company traded as high as $20.85 and last traded at $20.67. Approximately 1,298,200 shares were traded during trading, an increase of 2,574% from the average daily volume of 48,553 shares. The stock had previously closed at $20.59.
GENMAB A/S/S Stock Up 0.4 %
The business has a 50 day moving average of $23.86 and a two-hundred day moving average of $26.19.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Articles
- Five stocks we like better than GENMAB A/S/S
- ESG Stocks, What Investors Should Know
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What Are Dividend Challengers?
- Applied Materials Market Capitulates: Now is the Time to Buy
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
